Efficacy, safety, and tolerability of mirabegron in patients aged ≥65 yr with overactive bladder wet: a phase IV, double-blind, randomised, placebo-controlled study (PILLAR)-Reference-Cited by-同舟云学术

Efficacy, safety, and tolerability of mirabegron in patients aged ≥65 yr with overactive bladder wet: a phase IV, double-blind, randomised, placebo-controlled study (PILLAR)

Published:2020-02 Issue:2 Volume:77 Page:211-220
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Wagg Adrian,Staskin David,Engel Eli,Herschorn Sender,Kristy Rita M.,Schermer Carol R.

Funder

Astellas Pharma Global Development

Publisher

Elsevier BV

Subject

Urology

Reference32 articles.

1. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society;Abrams;Neurourol Urodyn,2002

2. Do we need a new definition of the overactive bladder syndrome? ICI-RS 2013;Drake;Neurourol Urodyn,2014

3. Prevalence and burden of overactive bladder in the United States;Stewart;World J Urol,2003

4. The prevalence of overactive bladder;Milsom;Am J Manage Care,2000

5. Real-world characteristics of elderly patients with overactive bladder in the United States;Ganz;Curr Med Res Opin,2016

Cited by 59 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. 2024 Revised Dutch guidelines for urinary incontinence: Addressing clinical bottlenecks through a modular approach;Continence;2024-12

2. Mirabegron 50 mg once daily, long-term treatment maximizes benefit in middle-aged and older people with overactive bladder syndrome: a systematic review and meta-analysis of nine phase II/III, randomized, double-blind, parallel-design, placebo-controlled, multicenter, and multinational trials;Frontiers in Surgery;2024-08-26

3. Assessment of urinary incontinence in older adults, part 2: treatment;Canadian Family Physician;2024-07

4. Evaluation and management of urinary incontinence in nursing home residents: unique considerations for an at-risk population;Gynecology and Pelvic Medicine;2024-06

5. Fragility of overactive bladder medication clinical trials: A systematic review;Neurourology and Urodynamics;2024-04-09